Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Department of Cancer Stem Cell Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Biomolecules. 2023 Feb 15;13(2):367. doi: 10.3390/biom13020367.
Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products and cell-bound complement activation products, are considered to be more sensitive than traditional complement markers, such as serum C3 and C4 levels and total complement activity (CH50), which become more widely used. In this review, we report the complement testing in the management of SLE over the last decade and summarize their utility.
系统性红斑狼疮（SLE）是一种免疫复合物沉积性疾病；因此，补体在 SLE 的发病机制中起着至关重要的作用。一般来说，血液中的补体水平和组织学检查中的补体沉积用于 SLE 的管理。因此，补体状态的评估可有助于 SLE 的诊断、疾病活动的评估以及治疗反应和预后的预测。此外，新型补体生物标志物，如裂解产物和细胞结合的补体激活产物，被认为比传统的补体标志物，如血清 C3 和 C4 水平以及总补体活性（CH50）更敏感，后者应用越来越广泛。在这篇综述中，我们报告了过去十年中 SLE 管理中补体检测的情况，并总结了它们的用途。
